Loading
A phase 2 trial of PRL3-zumab in advanced solid tumours, run by Intra-IMMUSG Pte Ltd, active and no longer recruiting.
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors is a phase 2 interventional study registered as NCT04452955 by Intra-IMMUSG Pte Ltd, with 51 participants enrolled, started 2020-12-12 and due to reach its primary completion in 2026-12-01. Interventions recorded: PRL3-zumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Intra-IMMUSG, PTP4A3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Intra-IMMUSG, PTP4A3, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Parexel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Parexel and the tag pipeline.
Shares Parexel and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/